Neta Goldschmidt

7.5k total citations
97 papers, 1.4k citations indexed

About

Neta Goldschmidt is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Neta Goldschmidt has authored 97 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pathology and Forensic Medicine, 41 papers in Genetics and 29 papers in Oncology. Recurrent topics in Neta Goldschmidt's work include Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (29 papers) and CNS Lymphoma Diagnosis and Treatment (20 papers). Neta Goldschmidt is often cited by papers focused on Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (29 papers) and CNS Lymphoma Diagnosis and Treatment (20 papers). Neta Goldschmidt collaborates with scholars based in Israel, United States and Germany. Neta Goldschmidt's co-authors include Tali Siegal, Moshe E. Gatt, Ora Paltiel, Alexander Gural, Osnat Bairey, Tamar Tadmor, Lev Shvidel, David Varon, Batia Avni and Rosa Ruchlemer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Neta Goldschmidt

92 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neta Goldschmidt Israel 23 514 425 355 331 268 97 1.4k
Pam McKay United Kingdom 21 763 1.5× 524 1.2× 355 1.0× 443 1.3× 139 0.5× 77 1.4k
Olivier Héquet France 18 323 0.6× 439 1.0× 324 0.9× 367 1.1× 169 0.6× 48 1.5k
Valéria Buccheri Brazil 18 398 0.8× 234 0.6× 471 1.3× 204 0.6× 216 0.8× 59 1.2k
Harpal S. Dhaliwal India 16 573 1.1× 334 0.8× 186 0.5× 487 1.5× 117 0.4× 35 1.3k
Itai Levi Israel 16 212 0.4× 245 0.6× 400 1.1× 206 0.6× 141 0.5× 60 844
Katsuji Shinagawa Japan 27 354 0.7× 259 0.6× 815 2.3× 548 1.7× 591 2.2× 108 1.9k
Ru Feng China 17 373 0.7× 273 0.6× 231 0.7× 319 1.0× 158 0.6× 93 998
Maria Antonietta Aloe Spiriti Italy 20 247 0.5× 598 1.4× 1.0k 2.8× 235 0.7× 483 1.8× 67 1.5k
Po‐Min Chen Taiwan 17 218 0.4× 166 0.4× 265 0.7× 461 1.4× 359 1.3× 80 1.2k
Ruth Achten Belgium 17 401 0.8× 216 0.5× 116 0.3× 254 0.8× 143 0.5× 34 1.1k

Countries citing papers authored by Neta Goldschmidt

Since Specialization
Citations

This map shows the geographic impact of Neta Goldschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neta Goldschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neta Goldschmidt more than expected).

Fields of papers citing papers by Neta Goldschmidt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neta Goldschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neta Goldschmidt. The network helps show where Neta Goldschmidt may publish in the future.

Co-authorship network of co-authors of Neta Goldschmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Neta Goldschmidt. A scholar is included among the top collaborators of Neta Goldschmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neta Goldschmidt. Neta Goldschmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kedmi, Meirav, Ohad Benjamini, Ginette Schiby, et al.. (2024). Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma. Hematological Oncology. 42(6). e70001–e70001.
2.
3.
Aumann, Shlomzion, Boaz Nachmias, Dina Ben Yehuda, et al.. (2023). Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality. European Journal Of Haematology. 111(1). 135–145. 1 indexed citations
4.
Assayag, Miri, Batia Avni, Shlomit Kfir‐Erenfeld, et al.. (2023). Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma. British Journal of Haematology. 202(1). 74–85. 15 indexed citations
5.
Karavani, Gilad, et al.. (2023). Prior exposure to chemotherapy does not reduce the in vitro maturation potential of oocytes obtained from ovarian cortex in cancer patients. Human Reproduction. 38(9). 1705–1713. 2 indexed citations
6.
Nachmias, Boaz, et al.. (2019). Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin’s lymphoma patients. Annals of Hematology. 98(11). 2561–2567. 4 indexed citations
7.
Joffe, Erel, Neta Goldschmidt, Osnat Bairey, et al.. (2018). Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. European Journal Of Haematology. 101(3). 399–406. 5 indexed citations
8.
Joffe, Erel, Osnat Bairey, Riva Fineman, et al.. (2017). Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. Hematological Oncology. 36(1). 128–135. 3 indexed citations
9.
10.
Goldschmidt, Neta, Geffen Kleinstern, Marina Orevi, et al.. (2016). Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Cancer Chemotherapy and Pharmacology. 77(5). 1053–1060. 16 indexed citations
11.
Mittelman, Moshe, Kalman Filanovsky, Yishai Ofran, et al.. (2016). Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol. Annals of Hematology. 95(11). 1811–1818. 5 indexed citations
12.
Amir, Gail, et al.. (2014). CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. Leukemia & lymphoma. 56(5). 1315–1319. 17 indexed citations
13.
14.
Cohen, Matan J., et al.. (2011). Large Vessel (Takayasu's) Arteritis in a Patient With Myelodysplastic Syndrome: Is There a Common Pathogenesis?. Clinical Lymphoma Myeloma & Leukemia. 11(1). 60–63. 13 indexed citations
15.
Rund, Deborah, Svetlana Krichevsky, Neta Goldschmidt, et al.. (2009). Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 114 adult patients. 2(15). 3 indexed citations
16.
Rund, Deborah, Svetlana Krichevsky, Neta Goldschmidt, et al.. (2005). Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia. 19(11). 1919–1928. 56 indexed citations
17.
Goldschmidt, Neta, E Libson, Allan I. Bloom, G Amir, & Ora Paltiel. (2003). Clinical utility of computed tomography-guided core needle biopsy in the diagnostic re-evaluation of patients with lymphoproliferative disorders and suspected disease progression. Annals of Oncology. 14(9). 1438–1441. 13 indexed citations
18.
Goldschmidt, Neta, Eduard Linetsky, Edna Shalom, David Varon, & Tali Siegal. (2003). High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 98(6). 1239–1242. 73 indexed citations
19.
Goldschmidt, Neta, et al.. (2003). Disseminated Mycobacterium kansasii infection with pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. American Journal of Hematology. 74(3). 221–223. 13 indexed citations
20.
Raz, Itamar, Yechiel Friedlander, Neta Goldschmidt, et al.. (2000). The Association between Two Common Mutations C677T and A1298C in Human Methylenetetrahydrofolate Reductase Gene and the Risk for Diabetic Nephropathy in Type II Diabetic Patients. Journal of Nutrition. 130(10). 2493–2497. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pam McKay Breakdown of academic impact, for papers by Olivier Héquet Breakdown of academic impact, for papers by Valéria Buccheri Breakdown of academic impact, for papers by Harpal S. Dhaliwal Breakdown of academic impact, for papers by Itai Levi Breakdown of academic impact, for papers by Katsuji Shinagawa Breakdown of academic impact, for papers by Ru Feng Breakdown of academic impact, for papers by Maria Antonietta Aloe Spiriti Breakdown of academic impact, for papers by Po‐Min Chen Breakdown of academic impact, for papers by Ruth Achten
Rankless by CCL
2026